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Somatostatin. The close interaction among these cell 
types in the Islets of Langerhans allows direct control on 
secretion of some of the hormones by other hormone 
involving paracrine control.[2] The glucagon secreted by 
α-cells of pancreatic islets is a member of the family 
of structurally related peptides that includes vasoactive 
intestinal peptide, gastric inhibitory peptide,[3] Secretin[4] 
and growth hormone releasing hormone.[5] In the 
pancreas, the glucagon is derived from preproglucagon, 
a 180 amino acids peptide precursor with a molecular 
weight of 3485 D and is composed of a single chain of 29 
amino acids and is identical in all mammals.[6] It consists 
of five separately processed domains, an amino terminal 
signal peptide followed by glicentin-related pancreatic 
peptide, glucagon, glucagon-like peptide-I and glucagon-
like peptide-II.[7]
INTRODUCTION
The pancreas is an elongated, some-what flattened 
retroperitoneal gland attached to the duodenum by a duct 
which serves to transport its digestive secretions into the 
intestine. It contains two major types of secretory tissues, 
reflecting its dual function as an exocrine and endocrine 
gland. The exocrine part constitutes about 99% of total 
volume of cells that are arranged as small cluster called 
acini. The remaining 1% of the tissue constitutes the 
endocrine portion of the pancreas and said as Islets of 
Langerhans, each only about 0.3 mm in diameter [1]
The Islets of Langerhans contains three distinct 
types of hormone secreting cells viz. α-cells secreting 
Glucagon, β-cells secreting Insulin, and δ-cells secreting 
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ABSTRACT
In the present study, pancreas of rats were dissected and transferred to HEPES buffer (25 mM, pH 7.4). The 
control tissue pieces were kept in culture medium for one hour and the treated tissues were kept in same 
medium for 30 minutes and incubated with Insulin (10 nm and 100 nm) for another half hour, then tissues 
were transferred to Bouin’s fixative (overnight at 40 ° Cc), cryosectioned (15 µm at -16 0 c) and subjected to 
immunocytochemical labeling with antibodies against Glucagon. Results: In the sections of control tissue, the 
Glucagon Immunoreactive Cells (GIC) were distinctly visible; on average 40-50 cells were counted in each 
islet. However in vitro treatment with 10 nm insulin caused 285.89 % increase in the GIC and was found to be 
highly significant (P<0.001). Whereas in 100 nm Insulin treatment, 206.41% increase in GIC was seen, this was 
significant with the control but non-significant with 10 nm Insulin treatment  
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The principal physiological action of glucagon is 
to increase blood glucose level when it falls below 
normal, mostly by its potent stimulation of hepatic 
glycogenolysis. This effect is mediated via stimulation 
of adenylyl cyclase and activation of cAMP- dependent 
protein kinase. Phosphorylase, the rate-limiting enzyme 
in glycogenolysis, is activated by glucagon as a result of 
cAMP- stimulated phosphorylation, while concurrent 
phosphorylation of glycogen synthase inactivates the 
enzyme; glycogenolysis is enhanced and glycogen 
synthesis is inhibited. It is interesting to note that 
glucagon has no effect on skeletal muscle glycogen, 
presumably because of the lack of glucagon receptors on 
skeletal muscle.[8] Apart from its hyperglycemic action, 
glucagon has a potent inotropic and chronotropic effect 
on the heart producing effect similar to -adrenoceptor 
agonist. In adipose tissue, glucagon stimulates adenylyl 
cyclase and increases lipolysis.[9]
The secretion of glucagon is regulated mainly by dietary 
glucose, insulin, amino acids, and fatty acids. [10] Glucose is 
one of the potent inhibitor of glucagon secretion. In vitro 
studies using isolated pancreatic islets from fed and from 
4 and 8-day fasted rats revealed a continue increase of 
glucagon during prolonged fasting.[11] Studies also revealed 
that various forms of stress such as trauma or infection 
are associated with hyperglucagonemia.[12] As a part of 
“fight or flight” response, enhanced sympathetic outflow 
and increased secretion of catecholamine could stimulate 
glucagon secretion. The concomitant insulinopenia would 
also promote glucagon secretion and allow mobilization 
of amino acids and free fatty acids respectively from 
muscles and adipose tissues.[13] Immunoreactive Calcitonin 
gene- related peptide (CGRP) has also been shown to 
occur in the fibers innervating blood vessels and islets and 
plays a key role in the regulation of glucagon secretion in   
rats.[14,15] It has been reported that glucagon secretion 
increases during hypoxia.[16] In addition to above 
pharmacological agents, Noradrenaline, adrenaline, 
acetylcholine and GABA were also found to influence 
the secretion of glucagon from rat pancreatic α-cells.  [17] 
Glucagon has emerged as an agent of considerable 
therapeutic value for the treatment of some diseases. 
The major use of glucagon is for emergency treatment 
of severe hypoglycemic reaction in insulin- dependent 
patients. Glucagon is sometime useful for reversing the 
cardiac effects of an overdose of beta- blockers as it 
increases cAMP production in the heart. Glucagon has 
also been used to relax the intestinal tract to facilitate 
radiographic ileography. Glucagon has been used for 
diagnostic purposes to distinguish obstructive form of 
hepatocellular jaundice.[18]
From the foregoing, it is clear that a number of factors 
are involved in the regulation of glucagon containing cells. 
However, these are based on a variety of techniques, and 
the available information does not permit unequivocal 
conclusions. In the present study, an attempt has been made 
to define the role of insulin in the regulation of glucagon 
secretion using an in vitro incubation system. The response 
of the glucagon cells was evaluated by selectively labeling 
the cells with antibodies against glucagon and processed 
for immunocytochemistry.
MATERIALS AND METHODS
Animals
Adult male Wistar rats weighing 175-200 g were used in 
the present study. They were housed in separate cages and 
maintained under natural photoperiodic conditions. Food 
and water were provided ad libitum. All the experiments were 
carried out between 9.00 to 11.00 hrs to avoid nyctohemeral 
influences, if any. The experiment protocol was approved 
by the Institutional Animal Ethical Committee of UDPS, 
Nagpur. The rats were anesthetized with chloroform and 
perfused transcardially with 200 ml of ice-cold phosphate 
buffered saline. The pancreatic tissue were dissected out 
and kept in HEPES buffered Hank’s balanced salt solution 
supplemented with 10% BSA (bovine serum albumin, pH 
7.4).
In vitro static incubation system
The tissue slices were given three washes in HEPES (25 
mM) medium and immediately transferred into small 
glass vials containing 1 ml of HEPES buffered Hanks 
balanced salt solution (HBSS; pH 7.4) supplemented with 
BSA and glucose (0.1% each). The tissue was kept in 
the static chamber that provides a constant temperature   
(17 0C) and supply of 95% O2 and 5% CO2. The control 
tissue fragments were incubated in the above medium for 
60 minutes. The experimental tissue fragments were pre-
incubated separately in  normal medium for 30 minutes, 
followed by 30 minutes incubation in the same medium 
containing Insulin at 10 and 100 nM concentrations. At the 
end of 60 min incubation, the tissue slices were fixed in 
Bouin’s fixative and kept overnight in the same fixative at 4 
0C. The tissues were then cryoprotected with 30% sucrose 
in phosphate buffer at 40C overnight. The tissues were then 
rapidly frozen with expanding CO2 and cut transverse plane 
at 15 µm thickness on a cryostat at -160C. The sections 
were mounted on poly-L-lysine- coated slides, dried and 
processed for immunocytochemistry using Streptavidin-
biotin method.
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Morphometric analysis
The islets of Langerhans of the control and treated samples 
were examined at 400X. Total of ten islets randomly 
chosen from each tissue sample were considered and the 
number of glucagon immunoreactive cells per islet was 
counted. The mean ± SE for each sample were calculated 
and the data was processed for statistical analysis and the 
difference between the control and experimental values 
was analyzed using Student’s t-Test and one-way Analysis 
of variance (ANOVA) followed by Tukey-Kramer multiple 
comparison test.
RESULTS
The islets of Langerhans constitute the endocrine 
portion of the pancreas. In the freshly collected tissue 
from the animals as well as the fragments of pancreatic 
tissue maintained in culture for 60 minutes; glucagon 
immunoreactive cells appeared in cluster along the 
Figure 1: Effect of insulin treatment on the population of glucagon 
secreting cells. Statistical analysis was carried out using one way 
ANOVA followed by Tukey-Kramer multiple comparison test.
**indicates p<0.001 compared to control, ns indicates p>0.05 compared 
to 10 nM insulin treatment.
Figure 2: T.S. through the control pancreas of rat showing glucagons 
secreting cells (arrow) in the islets of Langerhans (IL) immunolabeled 
with polyclonal antibodies against human glucagons. AC, acinar cells. 
X280.
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periphery of islets. Individual cells are prominent 
and show distinct nuclei. The cytoplasm in the cells 
is generally laden with immunoreactive material, no 
significant changes in the quality of immunoreactive 
or cytomorphological characteristics of cells could be 
noticed after incubation in the normal medium for 60 
minutes. This indicates that the static incubation system 
employed herein can protect the cellular integrity and 
appears to be suitable for the short-term culture studies.
The results of the effect of insulin on the population 
of glucagon are summarized in Figure 1. In the sections 
of control tissue, a limited number of glucagon 
immunoreactive cells were seen along the periphery of 
islets of Langerhans [Figure 2]. While the treatment with 
10 nM insulin caused a 285.89 % increase in the number 
of glucagon immunoreactive cells [Figure 3], which was 
found to be highly significant (P<0.001), 206.41% increase 
was observed following insulin treatment at 100 nM   
[Figure 4]. This change was also found to be highly 
significant as compared to control. However, no significant 
difference was found between cell population in the tissue 
samples treated with 10 nM and 100 nM concentration 
of insulin.
Figure 3: T.S. through the insulin treated (10 nM) pancreas sections. 
An increase in the number of immunoreactive cells can be seen. AC, 
acinar cells. X 280.
Figure 4: T.S. through the insulin-treated (100 nM) pancreas sections. 
An increase in the number of immunoreactive cells can be seen as 
compared to control. AC, acinar cells. X 280.J Young Pharm Vol 2 / No 2  147
DISCUSSION
The in vitro technique was found invaluable in the present 
study on regulation of glucagon cells in the rat pancreas. 
The assembly for in vitro incubation was quite convenient 
to set up. Since the tissue were incubated in microtiter 
plates, a small quantity of the medium and micro 
quantities of dosages was required to conduct the study; 
this made the system economical and permitted testing 
of large number of sample in a reproducible manner. 
Further, in vitro system provided environment free from 
secondary effects e.g. hormonal, neural, etc. that are 
encountered in in vivo and confound the interpretation of 
the results. Influences for internal and external cyclical 
factors like the photoperiod, estrous, and temperature 
were also avoided. The in vitro approach enabled us 
to circumvent recurrent painful conditions generally 
encountered in in vivo chronic studies. In vitro incubation 
permits the drug to act directly on the tissue and greatly 
reduce the response time. In the present investigation, in 
vitro incubation could be sustained for a period of one 
hour without any detrimental effect on the tissue. No 
differences were seen in the immunocytochemical profile 
of the freshly sectioned tissue and the tissue incubated 
in vitro for one hour; the cellular as well as cell nuclear 
profiles were quite similar in both the preparations. 
This confirms the suitability of in vitro technique for the 
present study. Several workers have fruitfully employed 
the immunocytochemistry method to investigate the 
cellular response in pancreas and other tissue.[19-21] Some 
information on the role of insulin in regulating glucagon 
secreting cells is also available using in vitro studies; 
Maruyama et al. 1984 reported intrapancreatic insulin in 
rat exerted an ongoing release inhibiting action on the 
alpha cells. Insulin was found to inhibit glucagon secretion 
by paracrine Beta- cells activity in human.  [22] Insulin was 
also found to inhibit the secretion of glucagon from 
chicken pancreas.[23] In the present study, the incubation 
of pancreatic tissue with insulin at both dose levels (10 
and 100 nM) resulted in significant increase in the number 
of Glucagon containing cells, the response at lower dose 
was more prominent than at higher dose. It seems that 
insulin may be influencing the secretory but not synthetic 
component of the glucagon cells physiology. As a result 
the intracellular hormonal content might be getting 
augmented in the alpha- cells resulting in the overall 
increase in their population.
REFERENCES
1.  Adeghate E. Distribution of calcitonin gene-related peptide, Neuropeptide-Y, 
vasoactive intestinal peptide, cholecystokinin-8, substance-P, and islet 
peptides in the pancreas of normal and diabetic rats. Neuropeptides 
1999;33:227-35.
2.  Adeghate E, Ponery AS, Pallot DJ, Singh J. Distribution of neurotransmitters 
and their effects on glucagon secretion from the in vitro normal and diabetic 
pancreatic tissues. Tissue Cell 2000;32:266-74.
3.  Bell GI, Sanchez PR, Laybourn PJ, Najarian RC. Exon duplication and 
divergence on the human pre-proglucagon gene. Nature 1983;304:368-71.
4.  Berstock DA, Wood JR, Williams R. The glucagon test in obstructive and 
hepatocellular jaundice. Postgrad Med J 1982;58:485-6.
5.  Bromer WW, Sinn LG, Staub A, Behrens OK. The amino acid sequence 
of glucagon. Diabetes 1957;6:234-8.
6.  Brown JC, Dryburg R. A gastric inhibitory polypeptide II. The complete 
amino acid sequence. Can J Biochem 1971;49:867-72.
7.  Gerich JE. Control of pancreatic IRG secretion in vivo. Metabology 
1976;25:1437-41.
8.  Guyton GM, Hall JE. Textbook of Medical physiology. 9th ed. Noida, India: 
Harcourt Brace and company Asia PTE Ltd.; 1998.
9.  Kahn CR, Shechter Y. Insulin, oral hypoglycemic agents and the 
pharmacology of endocrine pancreas. In: Gilman AG, Rall TW, Niles AS, 
Taylor P, editors. The Pharmacological basis of therapeutics. USA: Maxwell 
Macmillan International Editions; 1991. p. 1488.
10.  Karam JH. Pancreatic hormone and antidiabetic drugs. In: Katzung BG, 
editor. Basic and Clinical Pharmacology. Norwaik, USA: Appleton and 
Lange Books Pvt. Ltd; 1995. p. 652.
11.  Maruyama H, Hisatomi A, Orci L, Grodsky GM, Unger, RH. Insulin within 
islets is a physiologic glucagon inhibitor. J Clin Invest 1984;74:2294-9.
12.  Monsein LH, Halpert RD, Harris ED Feczko PJ. Retrograde ileography: 
Value of glucagon. Radiology 1986;161:558-9.
13.  Mutt V, Jorpes JE, Magnusson S. Structure of porcine secretin. The amino 
acid sequence. Eur J Biochem 1970;15:513.
14.  Narimiya M, Yamada H, Matsuba I, Tanese T, Abe M. The effect of 
hypoxia on insulin and glucagon secretion in the perfused pancreas of the 
rat. Endocrinology 1982;111:1010-3.
15.  Petterson M, Ahren B. Insulin and glucagon secretion in rats: effects of 
calcitonin gene-related peptide. Regul Pept 1988;23:37-50.
16.  Ponery AS, Adeghate E. Distribution of NPY and SP and their effects 
on glucagon secretion from in vitro normal and diabetic pancreatic tissues. 
Peptides 2000;21:1503-9.
17.  Prieto JC, Ortiz S, Sobrino F, Herrera MT, Bedoya F, Goberna R. Effect 
of prolonged fasting upon insulin and glucagon secretion from isolated rat 
pancreatic islets. Rev Esp Fisiol 1978;34:291-4.
18.  Spiess J, Rivier J, Thorner M, Vale W. Sequence analysis of a growth hormone 
releasing factor from human pancreatic islet tumor. Biochem 1982;12:6037-40.
19.  Unger RH. Glucagon and the insulin: Glucagon molar ratio in diabetes and 
other catabolic diseases. Diabetes 1971;20:834-8.
20.  Unger RH. Glucagon physiology and pathophysiology in the light of new 
advances. Diabetologia 1985;28:574-8.
21.  Eissele R, Goke R, Weichardt U, Fejmann HC, Arnold R, Goke B. Glucagon 
like peptide-1 immunoreactivity in gastroentero-pancreatic endocrine 
tumors: A light and electron microscopic study. Cell Tissue 1994;276:571-9.
22.  Asplin BC, Paquette TL, Plmer JP. In vivo inhibition of glucagon secretion 
by paracrine beta cell activity in man. J Clin Invest 1981;68:314-8.
23.  Honey RN, Weir GC. Insulin stimulates somatostatin and inhibits glucagon 
secretion from the perfused pancreas-duodenum. Life Sci 1979;24:1747-50.
Glucagon secreting cells responds to Insulin secretion in vitro using immunocytochemistry
Source of Support: Nil, Conflict of Interest: None declared.